



Market Announcement

24 May 2024

Anagenics Limited (ASX: AN1) – Trading Halt

Description

The securities of Anagenics Limited ('AN1') will be placed in trading halt at the request of AN1, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 27 May 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

ANAGENICS

24 May 2024

Attention: Lisa Banh
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

By Email: tradinghaltssydney@asx.com.au
Lisa.banh@asx.com.au

Dear Lisa

ASX Code: ASX:AN1 – Trading Halt Request

Pursuant to ASX Listing Rule 17.1, **Anagenics Limited** (ASX:AN1) (**Company**) requests a trading halt of its securities effective immediately.

The trading halt is requested pending the release of an ASX announcement in relation to the recent announcement made by Roquefort Therapeutics plc (ROQ) – “Midkine Antibody Licencing Deal” (23 May 2024) being an entity listed on London Stock Exchange (LSE) that Anagenics has a royalty agreement for midkine and other assets under its former Lynamid portfolio.

It is expected the trading halt will end on the earlier of the commencement of normal trading on Monday 27 May 2024, or when an announcement is released to the market.

The Company is not aware of any reason why the trading halt should not be granted.

Approved for release by the Board of Directors of Anagenics Limited.

Yours faithfully

Matthew Dudek
Company Secretary